The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) injections as an add-on therapy for adults with chronic obstructive pulmonary disease (COPD) who continue to struggle ...

Dupilumab reduced airway inflammation and mucus burden and enhanced airway volume and flow, which led to better lung function and improved asthma control in patients with moderate to severe type 2 ...

randomized to 300 mg of subcutaneous dupilumab or a placebo injection every 2 weeks. At 36 weeks, 20% of those treated with dupilumab achieved the primary endpoint of sustained disease remission ...

1 Dupilumab is being jointly developed by Regeneron ... Use DUPIXENT exactly as prescribed by your healthcare provider. It’s an injection given under the skin (subcutaneous injection).